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The competent immune system controls disease eﬀectively due to induction, function, and regulation of eﬀector lymphocytes.
Immunosurveillance is exerted mostly by cytotoxic T-lymphocytes (CTLs) while speciﬁc immune suppression is associated
with tumor malignancy and progression. In squamous cell carcinoma of the head and neck, the presence, activity, but also
suppression of tumor-speciﬁc CTL have been demonstrated. Functional CTL may exert a selection pressure on the tumor cells
that consecutively escape by a combination of molecular and cellular evasion mechanisms. Certain of these mechanisms target
antitumor eﬀector cells directly or indirectly by aﬀecting cells that regulate CTL function. This results in the dysfunction or
apoptosis of lymphocytes and dysregulated lymphocyte homeostasis. Another important tumor-escape mechanism is to avoid
recognition by dysregulation of antigen processing and presentation. Thus, both induction of functional CTL and susceptibility of
the tumor and its microenvironment to become T cell targets should be considered in CTL-based immunotherapy.
1.Introduction
Squamous cell carcinomas of the head and neck (SCCHN)
are the sixth most frequent type of malignancy worldwide.
SCCHN accounts for approximately 6% of all cancer
cases and for about 650,000 new cases and 350,000 deaths
worldwide each year [1–3]. While early-stage SCCHN can be
treated relatively eﬀectively, fewer than 40% of patients with
advanced, metastatic disease can be cured. Unfortunately,
about two thirds of patients with SCCHN present with
advanced-stage disease, commonly involving regional lymph
nodes.Distantmetastasesarefoundinabout10%ofpatients
at initial presentation. The 5-year survival for all stages is
about 60%. Despite signiﬁcant improvements in surgery,
radiation, and chemotherapy, long-term survival rates in
patients with advanced stage SCCHN have not signiﬁcantly
increased in the past 30 years [4–6].
Mortality from SCCHN remains high because of the
development of distant metastases and the emergence
of therapy-resistant local and regional recurrences. It is
therefore essential to develop a deeper understanding of the
biology of this disease for more eﬀective alternative therapies
such as immunotherapy. As basis for immunotherapeutic
approaches, interactions between tumors and the host
immune system have been a subject of many studies. It
has been shown that a naturally induced T-cell response
recognizing SCCHN exists that could potentially target and
possibly kill the tumor cells. Most cases in which this may
have happened will remain obscure because they never
become visible. Those cases that become clinically apparent
show a diﬀerent constellation. On one hand, antitumor
immune eﬀects can be observed; on the other, a deleterious
eﬀect on immune cells is exerted by the tumor. Tumor
progression itself is therefore invariably linked to selective
and pervasive impairment of immune cells.
The identiﬁcation and characterization of a variety of
humantumorantigenswithpossibleuseforimmunotherapy
and immunomonitoring [7] and expectations triggered by2 Clinical and Developmental Immunology
successful in vitro tests and therapeutic results in animal
models have led to rapid translation of these experimental
ﬁndings into clinical testing. This resulted in a rather
large number of patients with various types of malignant
diseases having been enrolled in clinical trials of T cell-
basedimmunotherapy. Inmanycasestumorantigen-speciﬁc
CTL immune responses could be achieved and successfully
monitored, but unfortunately these ﬁndings did not cor-
relate with clinical responses [8]. True clinical responses
attributable to immunotherapy have been sparse so far. This
discrepancy has initiated investigations into mechanisms
underlying the failure of tumor antigen-speciﬁc CTL to
control tumor growth in cancer patients, especially those
treated with immunotherapies. The mechanisms responsible
for this impairment may vary depending on the nature of the
tumor milieu and manifest in the tumor microenvironment
as well as in the periphery [9, 10].
For the development of strategies to prevent or reverse
tumor-induced eﬀects and to protect immune cells in
the tumor microenvironment, studies of both (a) nat-
urally occurring immune cells that could be recruited
for immunotherapeutic strategies targeting speciﬁcally the
tumor cells and (b) direct and indirect mechanisms respon-
sible for dysfunction and death of immune cells in SCCHN
are essential [11, 12].
This review focuses on the mechanisms of tumor-
mediated interference with the host immune system and
CTL in particular concerning SCCHN. We describe tumor-
escape mechanisms from the immune system at the tumor
site and in the periphery and describe strategies to redirect
the immune system to a more eﬀective antitumor response.
2. DistinctEtiologiesof Head andNeck Cancer
Two distinct causes of SCCHN are known. SCCHN is either
caused by the spontaneous accumulation of multiple genetic
alterations modulated by genetic predisposition and chronic
inﬂammation, enhanced by environmental inﬂuences such
as tobacco and alcohol abuse or by infection with oncogenic
human papillomavirus (HPV). Carcinogens are regarded
the most important factors. Thus, two main etiologies can
be deﬁned: tumors induced by toxic substances or by the
activityoftheviraloncogenesofHPV.Bothetiologiesinvolve
a multistep process and result in alterations aﬀecting two
large groups of genes: oncogenes and tumor suppressor
genes. However, it has been demonstrated that another set of
genes is also altered. These are related to immune response
mechanisms like the MHC complex. This observation is
important because it shows that immune recognition is
relevant and probably a force driving selection in the tumor
towards immune-resistant variants (see below).
HPV-associated SCCHN deﬁnes a distinct subgroup
that could speciﬁcally be targeted by novel preventive or
therapeutic measures. More than 100 human papillomavirus
(HPV) subtypes are known to date. Of these, 15 have been
showntobeoncogenicinhumans.HPVtype16and18seem
to play the major role in the etiology of HPV an associated
SCCHN, particularly those arising in the oropharynx [13,
14]. HPV infection has been detected in 20% to 30% of
tumors located in all head and neck anatomic subsites and in
about 50% of tonsil squamous cancers. For laryngeal cancer,
the role of HPV is less clear. Data on the prevalence of high-
risk HPV-associated SCCHN vary and multicenter studies
have not been performed yet [15, 16].
The lower rate of carcinogenic-risk factors and p53
mutations and a younger patient population suggests that
factors, currently unknown, are associated with viral entry,
propagation/transformation, and immune evasion in HPV-
associated SCCHN patients [14, 17]. Failure to clear HPV
infection leaves host cells under the inﬂuence of the
viral oncogenes. Persistently infected persons can develop
clinically or histologically recognizable precancers that can
persist and may develop over time into invasive cancer.
T h e s eo n c o g e n e sa r ev i t a lt ot h et u m o rc e l ls u r v i v a la n d
proliferation and therefore provide a suitable target for anti-
tumor vaccination.
Therefore, with these two diﬀerent etiologies, diﬀerent
treatment options according to the genesis of their malig-
nancy may be developed for future patients. Immunogenic
tumors in patients mounting speciﬁc immune responses
may be treated by induction or enhancement of speciﬁc
CTL responses. Such responses may have clinical impact for
primary therapy or in adjuvant settings when tumor burden
has been reduced.
3. Immunoresponses in SCCHN
3.1. Tumor-Speciﬁc T Cells. Eﬀective antitumor responses in
individuals with SCCHN depend on the presence and func-
tion of immune cells that are able to recognize and eliminate
tumor cells. These tumor antigen-speciﬁc T cells are known
to be present in the peripheral circulation and tissues of
patients with cancer. They can be monitored by multicolor
ﬂow-cytometry directly using tetrameric peptide-MHC class
I and II complexes, so called tetramers. These molecules
bind to the cognate T cell receptor. These stainings are
combined with T cell markers (e.g., CD3, 4, 8) and if desired
with makers for the diﬀerentiation (e.g., CCR7, CD45RA)
and the functional (e.g., CD107a, perforin, granzyme B) or
dysfunctional (e.g., annexin, 7-AAD, CD3-zeta-chain) status
of these cells.
A number of studies have investigated the frequency of
tumor-speciﬁcTcellsintheperipheralcirculationofpatients
and in the tumor [9, 10, 18–24]. In most of these studies,
T cells reactive against p53-derived epitopes by HLA-class-
I and II were described. The special interest in p53-derived
epitopes can be explained by the fact that the majority of
human cancers, including head and neck cancer, seem to
“overexpress” this protein. Other studies have focused on T
cells speciﬁc to HPV-derived epitopes [25].
Wild-type (wt) sequence p53 peptides like other tumor
epitopes are processed and presented to the host immune
cells either directly by the tumor cells or by professional
antigen presenting cells (APCs) such as dendritic cells
(DC). This results in an increased number of wt p53
peptide-speciﬁc T cells and, in some instances, p53-speciﬁc
antibodies [21, 26, 27].Clinical and Developmental Immunology 3
It could be demonstrated that the frequency of tetramer+
CD8+ T cells speciﬁc for the HLA-A2.1-restricted wt
p53264−272 peptide is signiﬁcantly higher in the peripheral
circulation of HLA-A2.1+ patients with head and neck
cancer than that in normal donors [27]. In a subsequent
study, the frequency of wt p53 epitope-speciﬁc T cells for
two distinct epitopes was determined in the peripheral
circulation and in tumor inﬁltrating lymphocytes (TIL)
isolated from SCCHN. Wt p53 epitope-speciﬁc T cells were
found to be signiﬁcantly enriched in the TIL, demonstrating
a preferential localization at the tumor site or in tumor-
involved lymph nodes [9]. Interestingly, the presence and
frequency of wt p53 epitope-speciﬁc eﬀector T cells among
TIL did not correlate with tumor stage. This implies that
the frequency of tetramer+CD8+ eﬀector cells alone has no
eﬀect on tumor progression. In this study, two patients with
suﬃcient numbers of TIL were available to test in vitro
responsiveness after polyclonal stimulation with anti-CD3
mAb. Only a low IFN-γ expression of the CD3+CD8+ Tc e l l s
could be measured indicating a poor responsiveness to this
stimulus. At the same time, a signiﬁcantly increased number
of regulatory T cells (Treg) were found at the tumor site
compared to the periphery [9]. It has been well accepted
that the presence and accumulation of Treg inhibits T-
cell responses in vivo and may be responsible in part, for
downregulation of antitumor immune responses in patients
with head and neck cancer [28]. Treg are likely to mediate
suppressive eﬀects directed at self-reactive T cells (see below
in detail) [29]. This immunosuppressive mechanism may be
particularly relevant to T cells that recognize self-peptides
like wt p53 epitopes and thus are likely to be tolerized,
especially at the sites of their accumulation in tumor
tissues. Other data also conﬁrm the depressed functionality
or even spontaneous apoptosis of CD8+ tumor-speciﬁc
Tl y m p h o c y t e s[ 10]. To date, the molecular mechanisms
drivingspontaneousapoptosisofcirculatingepitope-speciﬁc
T cells in patients with cancer are unknown. Diﬀerent
and from each other independent factors and mechanisms
like the Fas/FasL pathway, propriocidal lymphocyte death
[30], or tumor-derived factors responsible for disruption of
signal transduction pathways may play a role. The recent
discoveryofFasL+ microvesiclesinthecirculationofpatients
with head and neck and other cancers also suggests a
potential mechanism for systemic elimination of CD95+
activated CD8+ T cells. However, neither the tumor origin
of microvesicles present in patients’ sera nor their in vivo
participation in T cell apoptosis has been conﬁrmed.
A subgroup of head and neck cancer is associated
with human papilloma virus. Virus-derived antigens are
considered superior targets for T cells than tumor-associated
self-antigens because they have higher aﬃnity to MHC and
are more immunogenic. As opposed to tumor-associated
self-antigens, thymic negative selection of T cells recognizing
these virus derived antigens has not reduced the pool from
which tumor reactive T cells can be recruited. Therefore,
HPV-encoded oncogenic proteins, such as E6 and E7, are
promising tumor-speciﬁc antigens in addition to the fact
that they are considered obligatory for tumor growth.
Surprisingly, few studies have characterized endogenous T
cell immunity to HPV-encoded oncogenes in SCCHN as a
prerequisite for immunotherapeutic targeting of these anti-
gens. Two studies show an increased frequency of CD8+ T
lymphocytes directed against HPV E7 epitopes documenting
a natural immune response [18, 22]. These HPV-speciﬁc
T cells were able to recognize and kill a naturally HPV-16
transformed SCCHN cell line after IFN-γ treatment that
enhanced antigen processing and presentation by the tumor
cells. Further phenotypic characterization of the HPV-
speciﬁc T cells revealed an increase in terminally diﬀerenti-
ated/lytic T cells (CD8+CD45RA+CCR7−). This population
was also characterized by a high frequency of staining for
the degranulation marker CD107a in E7 tetramer+ T cells,
compared with bulk CD8+ T cells, consistent with their
terminally diﬀerentiated lytic, degranulated status. These
cells may account for the unsuccessful antiviral immune
response [31] to these tumors, indicating that incomplete
activation of tumors-peciﬁc T cells or suboptimal target
recognition may enable tumor progression in vivo. On the
other hand, if T cells from this reservoir could be adequately
activated and expanded, these cells could provide a valuable
reservoir of eﬀe c t o r sf o rc a n c e rv a c c i n a t i o n .
Several current studies suggest that cancer vaccines
have increased eﬃcacy if they incorporate tumor-speciﬁc
cytotoxic as well as helper epitopes. Although CTL are
considered to play the primary role in tumor eradication, it
is also hypothesized that the participation of tumor antigen-
speciﬁc CD4+ T-helper lymphocytes may be required for
optimal antitumor eﬀects by generating and maintaining
antitumorimmuneresponsesthroughinteractionswithCTL
and other cells [32, 33]. As a result, eﬀorts have been made
to deﬁne class II HLA-restricted tumor peptides for use
in cancer vaccines. As for CTL deﬁned epitopes, wild-type
sequence(wt)p53peptidesalsoprovideasourceforCD4+ T-
helpercells[20,34].Byexvivoexperiments,performedinan
autologous human system, the ability of anti-wt p53110−−124
CD4+ T cells to enhance the generation and antitumor
function of CD8 eﬀector cells was demonstrated. The results
emphasize the crucial role of T helper-deﬁned epitopes
in shaping the immune response to multiepitope cancer
vaccines targeting p53. This suggests that future vaccination
strategies targeting tumor cells should incorporate helper
and cytotoxic T cell-deﬁned epitopes [34].
4. Mechanisms of Tumor Evasion
4.1. Suppression of T Cells in the Cancer-Bearing Host.
Homeostasis of lymphocytes, that circulates through the
tissues and the blood, is maintained by refreshing the pool
viathethymicoutputofnaivelymphocytesandexpansionof
antigen-speciﬁclymphocytesuponadequatestimulationand
contraction of the lymphocyte pool by death of lymphocytes
intheperipherythathavecompletedtheirfunctions[35–37].
One of several mechanisms by which tumors escape
from the host immune system is induction of apoptosis in
eﬀector T cells [12]. It was shown that a proportion of
CD3+,F a s + T cells in the peripheral circulation were in
the process of apoptosis. This indicates that the Fas/FasL
pathway is involved in spontaneous apoptosis of circulating4 Clinical and Developmental Immunology
CD95 (Fas+) T lymphocytes. Interestingly, these cellsshowed
decreased expression of CD3-zeta-chain. Expression of T
cell receptor- or Fc-gamma receptor III-associated signal-
transducing zeta chain is important for the functional
integrity of immune cells [31]. Fas/FasL interactions might
lead to increased turnover of T cells in the circulation and,
consequently, to reduced immune competence in patients
withSCCHN[38].Thismaybeexplainedbyanimbalancein
the absolute counts of T-lymphocyte subsets and an overall
decreased absolute T cell count in patients not treated with
cytotoxic agents [39, 40]. The rapid turnover aﬀects mostly
T cells with eﬀector phenotype [41] that also show defects
in signaling [31]. Preferentially tumor-speciﬁc T cells are
aﬀected by apoptosis indicating a tumor-related eﬀect [10].
This observation can be explained further by the analysis
of TCR Vbeta proﬁles of CD8+ T cells in patients with
SCCHN that were altered relative to normal controls. This
may reﬂect increased apoptosis of expanded or tumor-
contracted CD8+ T cells, which deﬁne the TCR Vbeta proﬁle
of antigen-responsive T-cell populations in patients with
cancer [19]. Reports on T-cell apoptosis at the tumor site
and in the peripheral circulation [42, 43] support these
observations and suggest that death of tumor-inﬁltrating
lymphocytes (TIL), generally considered to represent tumor-
associated antigen-speciﬁc eﬀector cells, is driven by the
tumor or tumor-derived factors. Recent studies in SCCHN
also demonstrate that T regulatory cells (Treg) express
high levels of Fas and selectively kill CD8+ Te ﬀector cells
via Fas/FasL [44]. FasL is upregulated exclusively on Treg
isolated from patients with no evidence of disease after
receiving cancer therapy [44]. These FasL-expressing Treg
are resistant to apoptosis themselves but strongly suppress
and kill CD8+ eﬀector cells, adverting the cancer community
that traditional cancer therapy might contribute to tumor
progression by collaborating with the peripheral tolerance
process. In addition, Treg in patients with SCCHN kill CD4+
Te ﬀector cells via granzyme B in the presence of IL-2 [44].
S i g n a l i n gd e f e c t si nt h eT C Ra sw e l la sN F - Ba c t i v a t i o n
pathwaysinTILhavebeendescribedincomparisontoTcells
inﬁltrating inﬂammatory noncancerous sites. These defects
appear to be responsible for their loss of function [45].
Patients with tumors inﬁltrated by TIL expressing normal
levels of CD3-zeta-chain were found to have a better 5-
year survival than those showing loss of CD3-zeta-chain
expression [8, 46]. A high rate of apoptosis in TIL is
considered to be a factor for poor prognosis [47].
Taken together it appears that apoptosis of lymphocytes
intheperiphery aswellasatthe tumorsite leads torapid and
selective tumor-speciﬁc lymphocyte turnover followed by a
loss of eﬀector cells and thus failure to control tumor growth
in cancer patients.
4.2. Role of Regulatory T Cells. Because of the identiﬁcation
oftheforkheadboxtranscription factorFoxp3asanessential
transcription factor in CD4+ regulatory T cells (Treg), Treg
have been well characterized as a distinct lineage of T cells
[48]. Their thymic origin (denominated naturally occurring
Treg or nTreg) as well as their importance for the main-
tenance of peripheral tolerance under noninﬂammatory
conditions throughout the life span of an individual, has
been demonstrated in men and mice [49, 50]. When Foxp3+
Treg are depleted in an adult individual, fatal multiorgan
autoimmunity ﬁnally results [51] and the phenotype of this
disease is virtually indistinguishable from genetic deﬁciency
of Foxp3 that is characterized by a massive lymphopro-
liferative syndrome [52, 53]. However, the conditions and
mechanisms required to generate Foxp3+ Treg de novo in the
peripheral immune compartment (denominated inducible
Treg or iTreg) or to selectively expand Treg in peripheral
blood and lymphoid organs are less clear. Essential roles
of IL-2, TGF-β, and TCR signaling in iTreg generation,
expansion, function, and survival have been established
[54–56]. However, it is unclear which particular arm in
each of these pathways is important in FoxP3 regulation.
Foxp3 expression is required for suppressor capacity of Treg
in men and mice [57]. In addition, regulation of Foxp3
expression in nTreg as well as iTreg in response to acute
and chronic inﬂammation remains an unresolved issue.
Elucidating the signaling pathways that command Foxp3
induction and expression in inﬂammation constitutes a
challenge of particular interest as Treg induction, expansion,
survival, and function are signiﬁcantly altered in diseases in
which inﬂammation is a key regulator of the pathology (i.e.,
autoimmune disease and cancer).
It has become increasingly clear that malignant trans-
formation and cancer progression are immunologically
recognizable events and the immunologic status of the
host as well as the inﬂammatory conditions of the tumor
microenvironment inﬂuences signiﬁcantly the outcome of
the patient [58]. In early stages, inﬂammation at the
tumor site induces chemotaxis of immune cells from the
periphery to the tumor and immunologic recognition
may exert selective pressure, braking tumor growth of
the emerging cancer [59]. However, when the immune
system is confronted with persistent exposure to tumor
antigens the establishment of tolerance [60] and in con-
sequence immunosuppression of the patient are favored.
Much like tolerance to normal self-antigens, tolerance to
tumor antigens (TA) can arise from a failure to encounter
antigen or the deletion or functional inactivation of tumor-
speciﬁc T cells. It has been demonstrated during the last
10 years that Treg frequency increases in peripheral blood,
lymph nodes, and tumors of patients with several types
of cancer [61], including patients with HNSCC [62, 63].
It also correlates with tumor progression and outcome
[64]. Suppressor capacity and suppressor phenotype of
Treg isolated from SCCHN cancer patients are signiﬁcantly
increased in comparison to Treg isolated from healthy
subjects [62, 63], suggesting that enhanced function and
survival of suppressor cells might constitute one of the
mechanisms that are responsible for immunosuppression
of adaptive and innate immunity in these patients. Indeed,
in several models, tumor immunosurveillance is augmented
when CD4+CD25+ Tregs are depleted [65, 66]. Removing
Treg has also been shown to increase tumor immunity
elicited by vaccination [67].
Thus, one therapeutic possibility for restoration of anti-
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tumor antigen (TA)-speciﬁc Treg and to boost simultane-
ously TA-speciﬁc T helper and CTL responses. The fact that
Treg and activated T eﬀector cells share receptors and com-
mon metabolites in their diﬀerentiation, function, survival,
and expansion (i.e., IL-2) suggests that regulation of the
eﬀector and suppressor compartment is dichotomic. Thus,
one new challenge in modern immunotherapy is to under-
stand the signaling pathways that command the interplay of
eﬀector and suppressor responses in physiologic conditions
andininﬂammation.Adetailedknowledgeofthesepathways
might enable us to design immunotherapeutic strategies
that selectively promote expansion, survival, and function of
eﬀectororTregresponsesinpathologieswhereoneofthetwo
compartments is in disadvantage resulting in autoreactive
killer responses in the absence of Treg or in immunosup-
pression in the case of an excessive Treg response. Revert
immunosuppression in cancer to anti-tumor immunity is
essential to increase the quality and success of traditional
cancer therapy as well as the response to tumor vaccines.
Clinical trials for tumor vaccines using TA antigens and
antigenpresentingcells(APCs)orDCarenowunderwayfor
the treatment of diﬀerent types of cancer. To date, more than
1000 tumor vaccines have been reported [68]. The collective
results are encouraging but not satisfying. The study of
Chakraborty et al. shows that the MAGE-speciﬁc CTL
response in patients with melanoma contracts in circulation
byday28aftervaccination[69].Multiplefactorsmayexplain
the decline of TA-speciﬁc CTL in circulation of patients
after receiving a tumor vaccine. For example, the decline
might be a result of the activated CTL leaving the circulation
and homing into extravascular sites. The contraction might
also be a reﬂection of programmed cell death or activation-
induced cell death as physiologic homeostatic process [69].
However, the work of Zhou et al. suggests that contraction
might also result from a Treg cell regulated process. They
demonstrate that vaccination of the tumor-bearing host
expandsTreg,bluntingtheexpansionofna¨ ıvetumor-speciﬁc
Tcellsandblockingtheexecutionofeﬀectorfunctioninvitro
and in vivo [70]. The reports of Zhou et al. and Chakraborty
et al. suggest that the development of treatment paradigms
that seek to not only increase the frequency of tumor-speciﬁc
T cells but to do so in conjunction with strategies that selec-
t i v e l yi n a c t i v a t eo rr e m o v es u p p r e s s o rTc e l l si sam u s t .T h i s
objective has become even more complex with the recent
identiﬁcation of Th17 cells. Collectively, the amendment
of the Th1/Th2 paradigm by new subsets of T cells has
resolved some inconsistencies of the Th1/Th2 paradigm but
has also made the understanding of the pathogenic process
of cancer inﬂammation more complex. The fact that Th17
cell induction and diﬀerentiation is mediated by metabolites
that are also essential in Treg development and function
suggests that Treg-Th17 cell interactions might inﬂuence
the induction process of peripheral tolerance. Indeed, some
recent studies report that Th17 cells increase simultaneously
withTregincancersubjectsandthisdichotomicincreasecor-
relateswithcancerprogression[71].Thus,anewchallengein
cancer immunology has become to elucidate the population
dynamics and kinetics of Th17 and Th1 cells. Their interplay
and susceptibility towards regulatory mechanisms at the site
of inﬂammation and in the periphery possibly deﬁnes phase-
speciﬁc approaches for therapeutic interventions in order to
prevent cancer–inﬂammation-mediated tolerance.
First studies investigating the dynamics of Treg and
eﬀectorresponsesindicatethatmolecularsignalingpathways
in response to IL-2, TGF-β1, and the TCR are determinant
in regulating homeostasis of suppressor cell and eﬀector cell
populations [54–56, 79]. Therefore, a detailed knowledge of
these pathways might provide valuable insights on how Treg
might be regulated to support tumorrejection.
IL-2 plays a dominant role in vivo, in the maintenance
of immune system homeostasis and self-tolerance. The latter
function is emphasized by the ﬁnding that mice deﬁcient in
IL-2 or components of the IL-2 receptor (IL-2Rα or IL-2Rβ)
succumb to lymphoproliferative autoimmune syndrome,
with the eﬀect of IL-2Rβ lack being more severe [80, 81].
TGF-β1is a pluripotent cytokine that has pronouncedeﬀects
on T cell-mediated immune suppression as well as on the
control of autoimmunity. The role of TGF-β is in inﬂuencing
the constitutive expression of Foxp3. IL-2, the transcription
factor NFκB, might be essential in regulating Treg and T
eﬀector cell homeostasis in conditions of inﬂammation.
Elucidating the role of TGFβ and NF-κBi nT r e ga n dT
eﬀector cell dynamics is promising because both are up-
regulated during cancer inﬂammation and are common
regulators of Treg and Th17 cell diﬀerentiation. The design
of studies that elucidate these signaling pathways in patients
withcancerconstitutesonesteptowardsimmunotherapeutic
strategies that enforce immunogenicity of tumor vaccines.
Taken together, these complex immunoregulatory mech-
anisms lead to an immunoediting of the T cell and in
particular the CTL response by the tumor in order to avoid
elimination by the immune system. However, also the tumor
cell immunogenicity is edited by the immunoresponse.
4.3. Tumor-Immune Escape. Tumor-T cell interaction leads
to a negative selection pressure on tumor cells that are
being recognized by the immune system. T cell recognition
is therefore reduced in tumor cells by downregulation of
moleculesimportantforantigenprocessingandpresentation
or costimulation [82].
Several observations demonstrate an immune selection
of SCCHN tumor cells as discussed below. This selection
process and the resulting immune escape variants in the
tumor indicate that an eﬀective CTL response must have
taken place during the development of the malignancy. The
CTL-mediated cytolysis of immunogenic tumor cells is the
driving force of the selection process towards non-CTL-
susceptible tumor cell variants. The immune-evaded tumor
cells have several features making them resistant to further
natural CTL attack.
(a) Reduced expression of costimulating molecules on
the cell surface leads to inadequate T-cell activation,
even if the tumor is recognized and in turn to
tolerance induction [83].
(b) Expression of MHC class I is altered in up to 50% of
SCCHN [84–86]. Both, total loss of HLA-class I and
more selective downregulation of the HLA-A, B, or C
locus expression has been shown [87].6 Clinical and Developmental Immunology
Table 1: Tumor escape and potential reversal strategies by adjuvant treatment options.
Tumor evasion mechanism Desired eﬀect Potential reversal strategy
Loss of intracellular proteasomal antigen
processing, transport (TAP deletion) and
MHC-loading (beta2-microglobulin
deletion)
Restoration of antigen-processing and
MHC-loading, for suﬃcient tumor-antigen
presentation
Interferon-γ treatment of the tumor
Silencing of MHC genes Restoration of MHC-expression Interferon-γ treatment, application of
hypomethylating agents
Loss of T cell costimulation (e.g., CD80/86,
and CD54, CD58) Restoration of costimulatory molecules Toll-like receptor stimulation, interferon
treatment
Unfavourable microenvironment for
CTL-response
proinﬂammatory microenvironment for
CTL-response
Application of immune response modiﬁers,
suitable vaccine adjuvants, and induction of
CD4 T helper cells
Role of T cells
Too few tumor-speciﬁc T cells
Induction of more CTL with lytic activity,
broader T cell response including CD4
T-helper cells
Speciﬁc CTL stimulation and expansion.
Vaccination with single or multiepitope
vaccines including MHC class I and II
peptides. Induction and expansion of CD4
T-helper cells.
Loss of immunodominant tumor antigen Direction of the immune response to other
antigens or epitopes
Identiﬁcation of optimal MHC-class I and II
epitopes. Reexpression of the tumor-antigen
Suppressive Treg eﬀects Inhibition of deleterious T-cell eﬀects
Modulation/reduction of Treg by
pretherapeutic treatment with antibodies or
preferentially Treg targeting
chemotherapeutic agents
Tumor-induced T cell apoptosis Rescue of apoptotic T cells
Tc e l lp r o t e c t i o nb y :
(i) reversal of redox potential
(ii) treatment with anti-apoptotic drugs
(iii) blocking of proapoptotic molecules
(e.g., CD95)
(c) Expression of components of the antigen processing
machinery (APM), namely, LMP2, LMP7 and TAP1
is frequently downregulated or completely lost in
tumor lesions as compared to surrounding tissue as
well as in cell lines obtained from SCCHN cancer
patients. As a consequence of the downregulated
APM components, fewer antigen is processed and
loaded onto MHC-complexes that are by themselves
d e c r e a s e di nn u m b e ro rd y s f u n c t i o n a l .
In combination, these three mechanisms compromise
recognition of the progressed tumor by tumor-speciﬁc T
cells. In cell lines, the expression of APM-components
could be restored by incubation of with IFN-g [18, 88].
Furthermore, LMP2, LMP7, TAP1, TAP2, and HLA class I
antigen expression rates in primary SCCHN lesions were
found to predict overall survival [88]. Since expression of
APM-components could be functionally restored, structural
abnormalities such as genetic alterations are unlikely. With
regard to the two diﬀerent etiologies of SCCHN (one
being alcohol and tobacco abuse and the other oncogenic
human papillomavirus), more detailed studies are needed
to investigate if this dysregulation can be observed in
tumors with both etiologies. Whether this is a general
phenomenon, as has been reported in other tumor types
without viral etiologies, or is due to HPV speciﬁc factors,
as has been suggested in HPV-6- and HPV-11-associated
laryngeal papilloma [89], remains to be clariﬁed. So far, only
in one of our studies HPV-typing was carried out [18].
Tumors can also interfere with the immune system by
producing and releasing numerous factors that modulate
functionsofimmunecellsordirectlyinduceapoptosis.These
factors take action in the tumor microenvironment and
beyond.
5.Vaccination StrategiesAimingat
Inductionof CytotoxicCTL andReversing
Immune-EscapeMechanisms
For eﬀective vaccination, a successful stimulation of the
immune system and an eﬀective modulation of suppressive
eﬀects exerted by the tumor cells are necessary (Table 1).
5.1. Role of APM and Abnormal MHC Class 1 Expression.
Downregulation of dysfunction of APM components by the
tumor may disturb both the induction of tumor-speciﬁc T
cells in the initial phase of the immune response and sub-
sequently during the eﬀector-phase the proper recognition
of the tumor. This eﬀect is augmented by absent or reduced
presence of MHC class-I molecules on the cellular surface.
These cells are considered to have a more aggressive pheno-
type[90]whichmayalsobetheresultofimmunoselectionofClinical and Developmental Immunology 7
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(e.g., tobacco)
HPV persistence, together with genetic alterations, results in tumor initiation and progression over time
Figure 1: Immune escape variants of cells in the tumor indicate an eﬀective T cell response. HPV infection leads to unregulated cell
proliferation and accumulation of chromosomal aberration. Cumulative genetic alterations in tumor cell subclones lead to the emergence of
tumorcellvariantswithdivergentcharacteristics,forexample,lossofHLAexpression.Selectionpressureisexertedbythemicroenvironment
of the tumor and immune response mechanisms. Over time, susceptible cells will be eliminated and resistant cells will regrow, to form a
tumor consisting of predominantly immunoresistant cells and compromising immunotherapeutic strategies.
tumor cells able to evade the immunosurveillance (Figure 1).
The result can be seen by a low number of tumor inﬁltrating
lymphocytes and ineﬀective generation, activation, or even
enhanced apoptosis of tumor-speciﬁc T cells [9, 10, 18, 91].
In experimental systems, incubation of SCCHN cell lines
with IFN-γ was able to restore T cell recognition and killing
[18, 88]. These preliminary data should inspire more basic
and clinical research to better understand and further reﬁne
and develop these adjuvant strategies for clinical application.
From the current point of view, it seems indispensable to
combine APM- and MHC-class-I restoration with induction
of tumor-speciﬁc immune responses.
5.2. Apoptosis of T Cells. Tumor-induced increased apopto-
sis of lymphocytes, including NK-cells and tumor-speciﬁc
CD8+ T cells in the peripheral circulation and at the
tumor site, has been observed [10, 38, 41–43, 92]. This
phenomenon may lead to depletion of the lymphocyte pool
from which tumor-speciﬁc eﬀector cells could be recruited
or expanded by immunotherapy. Therapeutic approaches
should, therefore, aim to reverse this eﬀect by restoring a
normal lymphocyte turnover or protection of CD8+ Tc e l l s
from apoptosis [93].
5.3. Monitoring and Targeting Treg Responses in Patients with
Cancer: Therapeutic Relevance. The observation that Treg
are increased in peripheral blood and at the tumor site in
patients with cancer suggests that the development of treat-
ment paradigms that seek to not only increase the frequency
of tumor-speciﬁc T cells but to do so in conjunction with
strategies that selectively inactivate or remove suppressor T
cells is a must. However, the monitoring of Treg frequency
and function in patients with cancer is not only required
to improve the success of cancer vaccines and traditional
cancer therapy but might also provide a broader basis for the
development of more reliable prognostic factors, improving
a tumor-free outcome after therapy. On the other hand,
selective depletion of Treg in patients that have received
traditional cancer therapy might be essential to avoid or
decrease recurrent disease. We have shown that hema-
tologic recovery in response to oncologic therapy results
in expansion of the CD4+CD25+ compartment, including
CD4+CD25highFoxp3+ [62]. Importantly, not only was the
proportion of CD4+CD25+ T and CD4+CD25highFoxp3+
cells increased in the patients after receiving oncologic
therapy, but suppressor function and survival of these
cells were signiﬁcantly elevated. The observed expansion of
Treg expressing Foxp3 correlated with increased suppression
mediated by these cells in patients with non evident disease
[62]. The eﬀect of oncologic therapy on Treg might be
related to two phenomena: (i) homeostatic regulation after
radio/chemotherapy-induced lymphopenia resulting in the
expansion of a total lymphocyte pool, and (ii) activation and
expansion of de novo induced Treg and T responder cells by
inﬂammatory cytokines derived from the strong inﬂamma-
tory response that usually accompanies radio/chemotherapy.
The immune system controls the level and the activation
state of each cellular compartment through homeostatic
regulation, a process that is triggered during development
and after the induction of a lymphopenic state by external
stimuli[94].Radio/chemotherapymayhaveprofoundeﬀects
on the peripheral blood cell count, due to an increase
in the availability of homeostatic cytokines and increased
interactions of T cells with APC. It has been proposed
that lymphodepletion removes endogenous cellular elements
that act as sinks for cytokines, which are responsible for
augmenting the activity of tumor-reactive T cells [95].
Thus, T-cells surviving after therapy receive very strong
stimuli (cytokines and enhanced APC-T cell interactions)
that trigger T-cell activation and expansion. Several groups8 Clinical and Developmental Immunology
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Figure 2: Comparison of the eﬀects of a failed conventional therapy and the outcome of a hypothetical CSC-targeted immunotherapy.
Currently applied conventional therapies target bulk tumor cells that are less resistant than CSC. This leads to initial shrinking of the tumor
mass but eventually regrowth from residual CSC. An immunotherapeutic approach targeting CSC directly would cut oﬀ the rejuvenating
supply of CSC and ultimately lead to tumor regression.
Table 2: Examples for studies targeting CSC with CTL.
Target Tissue Ref
Dendritic cells loaded with CSC as antigen source glioblastoma [72]
CD8 deﬁned ALDH1-speciﬁc T-cell epitope HNSCC [73]
Vaccination with murine prostate stem cell antigen encoding cDNA Murine prostate cancer [74]
Dendritic cells loaded with neurospheres from brain glioma cells Murine glioma [75]
Identiﬁcation of 2 CD8 deﬁned prostate stem cell antigen-speciﬁc T-cell epitopes Prostate cancer [76]
Vaccination with deﬁned human embryonic stem cells (hESCs) or induced pluripotent stem (iPS) cells Colon cancer [5]
CD8 deﬁned SOX2-speciﬁc T-cell epitopes Glioma [77, 78]
have reported that antitumor responses seen after adoptive
transfer of tumor-reactive T cells into lymphodepleted
hosts are signiﬁcantly increased [96, 97]. In this context,
it is reasonable to suggest that a similar mechanism (s)
is involved in activation and expansion of the activated T
responder and memory T-cell compartments in SCCHN
patients who receive oncologic therapy. Concomitantly, the
Treg subset is signiﬁcantly expanded. These ﬁndings suggest
that monitoring of Treg frequency and function as well as
depletion of Treg after oncologic therapy might be crucial
to allow the development of an eﬀective antitumor T-cell
response able to eliminate secondary tumors.
5.4.Single-andMulti-T-CellEpitopeVaccines. p53mayserve
as a model antigen for the development of broadly applicable
antitumor vaccines in SCCHN. A number of p53-derived
epitopes that can be used for the design of vaccines have
been identiﬁed [98, 99]. Since mutations in the p53 sequence
are frequent [100], epitopes incorporating these mutations
would have to be tailored speciﬁcally to each patient.Clinical and Developmental Immunology 9
Therefore,epitopescomposedofthewild-type(wt)sequence
are especially attractive, since they are shared among the
same HLA type and are therefore not patient speciﬁc.
In vitro stimulation of CD8+ T cells with wt p53 peptide-
pulsed autologous dendritic cells can be used to induce
eitherHLA-A2-restricted, wt p53149−157 and/or wt p53264−272
peptide-speciﬁc responses from epitope-speciﬁc precursors.
Interestingly, using these single epitopes, wt p53 peptide-
speciﬁcCD8+ Tcellsweregeneratedinonlyathirdofhealthy
donors or subjects with cancer [27]. Others have reported
comparable ﬁndings [101, 102]. The limited responsiveness
of healthy donors may be explained by negative thymic
selection of T cells with receptors speciﬁc for self-antigens.
It can be expected that especially T cells with high-aﬃnity
receptors are eradicated. The observed limited responsive-
ness to HLA class I-restricted wt p53 peptides among HLA
class I-compatible healthy donors and subjects with cancer
suggests that multiple wt p53 peptides are needed in order to
maximize donor responsiveness. The underlying causes can
only be suspected and may partly be due to the mechanisms
of tumor immune evasion discussed above.
S i n c ei tm a yp r o v ed i ﬃcult to determine in an individual
case the responsiveness prevaccination, a vaccine consisting
of more than one epitope may be the more promising
approach.
5.5. Immune Intervention Approaches For HPV-Associated
SCCHN. Oncogenic HPV genotypes, particularly the HPV
types 16 and 18, are found in a subset of SCCHN mostly
lacking the risk factors of alcohol and tobacco abuse. It
therefore seems to be a suitable malignancy for vaccination
against HPV-associated targets. Thus, these HPV-associated
SCCHN may be preventing by (a) the existing prophylactic
HPV-vaccines or (b) treated by vaccines designed to induce
an appropriate antitumor immune response against HPV-
speciﬁc tumor antigens [18, 22]. Lately, several authors
have advocated a combined approach of prophylactic and
therapeutic HPV-vaccination in patients with dysplasia and
risk for reinfection with oncogenic HPV-types [103, 104].
(a) Prophylactic HPV Vaccines. Neutralizing antibodies spe-
ciﬁc for the viral capsid proteins may prevent infection by
HPV. Prophylactic HPV vaccines have been developed and
approved. As antigen, they contain capsid protein L1 of
the most prevalent HPV types. They were introduced in
2006 and have the estimated potential to reduce the burden
of cervical cancer, the tumor entity they were originally
developed for, by approximately 70% [105, 106] and the
vaccine type-related precancers. Estimations for SCCHN are
currently not available. Prophylactic HPV vaccines have,
however, no therapeutic potential due to their mechanism
of action via virus-neutralizing antibodies targeting the L1
capsid antigen. Unfortunately, this capsid protein is not
expressed in persistently HPV-infected basal epithelial cells
and transformed cells in infected mucosa and is therefore
uselessfortherapeuticvaccination.Accordingly,prophylactic
vaccines have not shown any therapeutic activity [107].
However, they may be of beneﬁt in posttherapeutic sit-
uations where infected lesions have been removed surgically
to prevent formation of new lesions due to reinfection [104].
These settings are currently under investigation.
(b) Therapeutic HPV Vaccines. The rationale for vaccines
targeting HPV-associated SCCHN is that virus-related
oncogenes are obligatory to tumor growth. Vaccines with
therapeutic potential must target the two HPV oncogenic
proteins, E6 and E7 as antigens that are important in
the induction and maintenance of cellular transformation
and are coexpressed in the majority of HPV-associated
carcinomas. Two studies have investigated if an endogenous
T-cell immunity to HPV-encoded oncogenes E6 and E7 in
SCCHN patients exists [18, 22]. This group of T cells would
havethepotentialtospeciﬁcallyidentifyandtargetthetumor
upon appropriate activation. Therefore, these cells are a
critical prerequisite for the development of vaccine-based
strategies for enhancing antitumor immunity in patients
with HPV+ tumors. Indeed, in both studies it was found that
infection with HPV-16 (as compared to uninfected control
individuals) signiﬁcantly alters the frequency and functional
capacity of virus-speciﬁc T cells in SCCHN patients. In
addition to the presence of HPV-speciﬁc eﬀector T cells, suc-
cessful tumor elimination requires that HPV-infected tumor
cells function as appropriate targets for cytotoxic T lympho-
cyte recognition and elimination. Immunohistochemistry
of HPV-16+ SCCHN tumors showed that the antigen-
processing machinery components are downregulated in
tumors compared to adjacent normal squamous epithelium
[18]. Thus, immunity to HPV-16 E7 is associated with the
presenceofHPV-16infectionandpresentationofE7-derived
peptides on SCCHN cells, which shows evidence of immune
escape comparable to cervical cancers [108]. These ﬁndings
suggest that development of E7-speciﬁc immunotherapy in
HPV-associated SCCHN should be combined with strategies
to enhance the antigen processing machinery component
expression and function [18].
6.T-CellTherapiesDirectedto
Cancer Stem Cells
Tumors consist of heterogeneous populations of cells.
According to the cancer stem cells (CSCs) hypothesis, CSCs
are a subpopulation of the tumor more capable than other
cells to self-propagate, initiate new tumors diﬀerentiate
into bulk tumor, and therefore sustain tumor growth.
Because of these properties, CSCs have been moved into the
focus of targeted therapies. The current knowledge of the
existence of CSCs begins to lead to studies of their speciﬁc
elimination(Figure 2andTable 2).Itisbeingenvisionedthat
the targeting of CSC in combination with the established
therapeutic modalities such as radiation and chemotherapy
thatduetoarelativeresistanceoftheCSCmorepreferentially
kill the bulk of the tumor may decrease the frequency of
recurrences and enhance the patient’s long-term survival.
Therefore, the development of strategies that target the CSC
populationdirectlyishighlydesirable.EliminatingCSCleads
to an abrogation of the replenishing pool of cancer cells and
ultimately leads to petering out the tumor growth, as has
been documented in animal experiments where removal of10 Clinical and Developmental Immunology
CSC and transplantation of only the non-CSC tumor cells
did not lead to sustained tumor growth.
The development of CSC targeted therapy has to over-
come three major hindrances, that relatively to the bulk
tumorpopulationareincreased(i)chemoresistance,(ii)resi-
stance to radiotherapy, and (iii) immunescape mechanisms.
Since radio- and chemotherapies have already been
optimized towards the limits of clinical beneﬁt and yet
tolerable side eﬀects, a very attractive alternative approach
of speciﬁcally targeting CSC is to develop antitumor T cell
vaccines. One of the possible reasons that these therapies
lacked eﬃcacy in past clinical trials could be attributed
to the fact that rather bulk tumor than CSC have been
targeted. This may change with the identiﬁcation of tumor-
speciﬁc epitopes derived from CSC markers. One such as
CSC model-target for head and neck cancer and others
is the recently described CD8 deﬁned T-cell epitope of
aldehyde dehydrogenase-1 (ALDH1) [73]. Examples of other
such CD8 deﬁned T-cell epitopes are available for prostate
stem cell antigen [76]. Less well-deﬁned approaches include
the development of a CSC-dendritic cell vaccine [72].
Recent studies using animal models for prostate cancer and
malignant glioma demonstrated the potential of diﬀerent
vaccination strategies (dendritic cells, gene-gun and virus)
targeting CSC in cancer immunotherapy [74, 75]. It was
suggested recently that stemness related proteins expressed
in CSC might also be a source for tumor antigens. Tumor
types most dependent on CSC for their growth kinetics were
namedtobethebestsuitedforapproachestargetingstemcell
genes [109].
In several studies, the eﬃcacy of potential therapies
directed against stem cell-associated signaling pathways are
tested. For example, T cell immunity against embryonic
stem cells antigen SOX2 and SOX6 has been explored in
glioma stem cells [77, 78]. Since the expression of stemness-
related genes is a common feature of stem cells and CSC,
the question of vaccine induced autoimmunity to stem cells
will have to be addressed by scientists following this path.
One example is the vaccination with embryonic stem cells
(ES) or induced pluripotent stem cells (iPS) that has been
shown to induce protective immunity in colon carcinoma
[110]. Another group used dendritic cells (DC) generated
from mouse and human ES or iPS as a means for anti-cancer
immunotherapy [111].
Success of these potential therapies will depend on how
well immunological responses to CSC can be modulated
for example by vaccine adjuvants upregulating antigen
processing and presentation. Recently, a reduced activity of
the 26S proteasome in breast cancer cells and in gliomas
was observed as a feature of CSC [112]. Proteasomes are
thought to play an important role in antigen processing
and presentation of antigens in association with HLA class
I[ 113]. This may result in reduced antigen processing and
presentation of peptides presented to the immune system
on major histocompatibility complex -I molecules. Reduced
proteasomalactivitywasalsousedasexplanationforthehigh
expression levels of known stem cell markers like BMI-1 and
nestin in CSC, which are both substrates of the proteasome
[114, 115].
7. Signiﬁcance of CSC for Future
TreatmentStrategies
The classiﬁcation of conclusive CSC markers followed by the
identiﬁcation of deﬁned T cell-recognized CSC epitopes in
the future may lead to the clinical application of anti-CSC
vaccinationstrategies.Severalapproachesarecurrentlybeing
evaluated (Table 2). Whether targeted therapies directed
against stem cell-associated signaling pathways, which may
be activated in stem cells and in CSC, will be of clinical use
or be limited by undesirable side eﬀects in vivo remains so
far unresolved.
8. Conclusion
Immunotherapy is considered an attractive treatment moda-
litybecauseitspeciﬁcallytargetsthecanceravoidingormini-
mizing side eﬀects. Ideally, its therapeutic eﬀects will also
reach distant metastasis and will be sustainable lasting beyo-
nd the presence of the cancer due to immunologic memory.
Therapeutic strategies should consider that SCCHN has
at least two distinct etiologies. One is chronic alcohol and
tobacco abuse and the other is related to oncogenic human
papillomavirusinfectionandtransformation.Bothetiologies
will diﬀer signiﬁcantly in the antigenic make up of the
tumor cells based on presence of self or viral antigens,
respectively. In both cases, however, immunotherapeutic
approaches should aim at induction of adequate antigen
processing and presentation by the tumor cells to become
visible for the immune system as target. Furthermore, tumor
induced immune dysregulation should be redirected in favor
of tumor rejection and ﬁnally an adequate stimulation of
eﬀector T cells capable of in vivo expansion and survival
in the tumor-microenvironment is thought critical for
improving clinical results.
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